Langerhans cell histiocytosis in a child with multisystemic lesions associated with infected poliomyelitis and SARS-CoV-2, features of diagnostics. Clinical case
DOI:
https://doi.org/10.15574/SP.2023.129.72Keywords:
Langerhans cell histiocytosis, poliomyelitis, СOVID-19, cytostatic therapy, childrenAbstract
Langerhans cell histiocytosis (LCH) is an abnormal clonal proliferation of Langerhans cells. The prognosis varies depending on the form of the disease and organ damage. Any organs and systems can be involved in the pathological process in various combinations. A poor response to standard therapy and an unfavorable prognosis are characteristic of patients with a multisystem form of LCH and involvement of organs at risk. Skin lesions are a classic sign of LCH.
Purpose - to describe the complexity and duration of diagnosis of LCH with multisystem damage in a boy aged 2 years and 2 months, infected with poliomyelitis and coronavirus.
Clinical case. The first clinical manifestations of LCH in the child debuted with an eczematous-seborrheic rash on the scalp with spread to the limbs and trunk. The child was treated for toxicoderma, hemorrhagic vasculitis at the place of residence for 6 months. The boy lost 1.5 kg of body weight in 1 month. At the time of hospitalization, seborrheic-eczematous rashes on the skin with a hemorrhagic component, trophic-inflammatory changes in the nails of the hands, signs of protein-energy deficiency, stomatitis, gingivitis, hepatosplenomegaly, polyserositis, diabetes insipidus, osteolytic foci of the frontal bones were found. Results of the tests: anemia, thrombocytopenia, hypoproteinemia and hypoalbuminemia, coagulation disorders. The patient had the onset of lower flaccid paraparesis, muscle hypotonia. The boy was diagnosed with a number of infectious complications, including poliomyelitis (a derivative of vaccine poliovirus type 2), COVID-19. The child received LCH-III cytostatic therapy with a positive effect.
The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
References
Abdull Gaffar B, Awadhi F. (2020). Oral manifestations of Langerhans cell histiocytosis with unusual histomorphologic features. Ann Diagn Pathol. 47: 151536. https://doi.org/10.1016/j.anndiagpath.2020.151536; PMid:32454442
Ahuja A, Uppe A, Nair G. (2018). Multisystem Involvement of Langerhans Cell Histiocytosis. J Assoc Physicians India. 66 (4): 75-76.
Aricò M, Astigarraga I, Braier J, Donadieu J, Gadner H, Glogova E et al. (2015). Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood. Br. J. Haematol. 169: 241-248. https://doi.org/10.1111/bjh.13271; PMid:25522229
Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A et al. (2020). Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med. 383: 2586-2588. https://doi.org/10.1056/NEJMc2031670; PMid:33259154 PMCid:PMC7722690
Baillet A, Grange L, Lafaix PA, Gaudin P, Juvin R. (2007). Radiculopathy as a manifestation of Langerhans' cell histiocytosis. Joint Bone Spine. 74 (2): 190-193. https://doi.org/10.1016/j.jbspin.2006.05.013; PMid:17344085
Bano S, Chaudhary V, Narula MK, Anand R, Venkatesan B, Mandal S, Majumdar K. (2014). Pulmonary Langerhans cell histiocytosis in children: a spectrum of radiologic findings. Eur J Radiol. 83 (1): 47-56. https://doi.org/10.1016/j.ejrad.2013.04.044; PMid:23769766
Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G et al. (2021). Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J. 11: 115.
Barclay M, Devaney R, Bhatt JM. (2020). Paediatric pulmonary Langerhans cell histiocytosis. Breathe (Sheff). 16 (2): 200003. https://doi.org/10.1183/20734735.0003-2020; PMid:32684994 PMCid:PMC7341617
Center for Public Health of the Ministry of Health of Ukraine. (2022). In 2021 the level of vaccination coverage of children against poliomyelitis was 80%. URL: https://phc.org.ua/news/u-2021-roci-riven-okhoplennya-scheplennyami-ditey-proti-poliomielitu-buv-80.
Cesaro S, Ljungman P, Mikulska M, Hirsch HH, von Lilienfeld-Toal M, Cordonnier C et al. (2022). Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 36: 1467-1480. https://doi.org/10.1038/s41375-022-01578-1; PMid:35488021 PMCid:PMC9053562
Coronavirus Pandemic (COVID-19). (2022). Coronavirus country by country. URL: https://ourworldindata.org/coronavirus#coronavirus-country-profiles.
Czyzewski K, Galazka P, Zalas-Wiecek P, Gryniewicz-Kwiatkowska O, Gietka A, Semczuk K et al. (2019). Infectious complications in children with malignant bone tumors: a multicenter nationwide study. Infect Drug Resist. 12: 1471-1480. https://doi.org/10.2147/IDR.S199657; PMid:31213862 PMCid:PMC6549759
Dhar S, Srinivas SM, Dhar S, Basu S, Banerjee R, Malakar R et al. (2020). Langerhans cell histiocytosis in children: A retrospective case series of 126 cases. Pediatr Dermatol. 37 (6): 1085-1089. https://doi.org/10.1111/pde.14389; PMid:32981115
Donadieu J, Héritier S. (2017). Child Langerhans cell histiocytosis. Presse Med. 46 (1): 85-95. https://doi.org/10.1016/j.lpm.2016.09.013; PMid:28087208
Dorosh O, Masynnyk J, Tsymbalyuk-Voloshyn I. (2021). Features of the Course of Herpes Encephalitisin a Child with Acute Lymphoblastic Leukemia in Remission. Abstract Number: 543. Conference: 53rd Congress of the International Society of Paediatric Oncology (SIOP 2021). Honolulu, Hawaii, USA. Pediatric Blood & Cancer Journal (PBC). 68 (S5): 452-453. https://doi.org/10.1002/pbc.29349; PMid:34662504
Dorosh OI, Tsymbaluk-Voloshyn IP, Polishchuk RS, Dubey LYa, Vorobel OI, Kozlova OI et al. (2014). Langerhans Cells Histiocytosis: Features of Clinical and Laboratory Manifestations and the Course of the Disease. Zdorov'e rebenka. 5 (56): 40-49. URL: https://doaj.org/article/000c9c2670064f36962ba9e0407b25d5. https://doi.org/10.22141/2224-0551.5.56.2014.76242
Efremova EV, Vasil'chev AV, Shutov AM, Podusov AS, Troshina IYu, Timofeev AA. (2019). Case of Gullian-Barre. Syndrome in a Pftient with Pulmonary Langerhans Cell Hystiocytosis. Аrkhiv vnutrennei meditsyny. 9 (5): 399-402. https://doi.org/10.20514/2226-6704-2019-9-5-399-402
Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J et al. (2016). Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 127: 2672-2681. https://doi.org/10.1182/blood-2016-01-690636; PMid:26966089 PMCid:PMC5161007
Gadner H, Minkov M, Grois N, Potschger U, Thiem E, Arico M et al. (2013). Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 121: 5006-5014. https://doi.org/10.1182/blood-2012-09-455774; PMid:23589673
Gargano F, Welch JJ, Klinge PM, Sullivan SR, Taylor HO. (2019). Langerhans Cell Histiocytosis in the Pediatric Population: Treatment of Isolated Craniofacial Lesions. J Craniofac Surg. 30 (4): 1191-1193. https://doi.org/10.1097/SCS.0000000000005249; PMid:31166264
Glenthøj A, Jakobsen LH, Sengeløv H, Ahmad SA, Qvist K, Rewes A et al. (2021). SARS-CoV-2 infection among patients with haematological disorders: severity and one-month outcome in 66 Danish patients in a nationwide cohort study. Eur J Haematol. 106: 72-81. https://doi.org/10.1111/ejh.13519; PMid:32939853
Gómez-De Lara JL, Rodríguez-Paz CA. (2021). Historical, clinical and epidemiological aspects of poliomyelitis in Mexico (1946-1960). Rev Med Inst Mex Seguro Soc. 59 (6): 585-590.
Grois N, Prayer D, Prosch H et al. (2005). Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain. 128 (4): 829-838. https://doi.org/10.1093/brain/awh403; PMid:15705614
Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. (2008). Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr. Blood Cancer. 51: 71-75. https://doi.org/10.1002/pbc.21498; PMid:18260117
Han D, Li F, Yahya WH, Ge R, Zhao Y, Liu B, Zhou Y, Wen Z. (2022). Multisystem Langerhans Cell Histiocytosis in Younger Infants First Presenting in Skin. J Pers Med. 12 (7): 1024. https://doi.org/10.3390/jpm12071024; PMid:35887522 PMCid:PMC9315804
Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R et al. (2013). Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Euro Histio Network. Pediatr Blood Cancer. 60 (2): 175-184. https://doi.org/10.1002/pbc.24367; PMid:23109216 PMCid:PMC4557042
Jones KM, Balalla S, Theadom A, Jackman G, Feigin VL. (2017). A systematic review of the worldwide prevalence of survivors of poliomyelitis reported in 31 studies. BMJ Open. 7 (7): e015470. https://doi.org/10.1136/bmjopen-2016-015470; PMid:28694346 PMCid:PMC5734404
Kalra A, Kalra K, Agarwal MC, Bhatia R. (1986). Hand Schuller Christian disease with multiple pareses. Indian Pediatr. 23 (7): 566-567.
Krafchik B, Pope E, Walsh SRA. (2005). Histiocytosis of the skin in children and adults. In: Weitzman S, Egeler M, editors. Histiocytic disorders of children and adults. Cambridge: UK: Cambridge University Press: 130-153. https://doi.org/10.1017/CBO9780511545252.008
Krooks J, Minkov M, Weatherall A. (2018). Langerhans cell histiocytosis in children: Diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up. J. Am. Acad. Dermatol. 78: 1047-1056. https://doi.org/10.1016/j.jaad.2017.05.060; PMid:29754886
Krooks J, Minkov M, Weatherall AG. (2018). Langerhans cell histiocytosis in children: History, classification, pathobiology, clinical manifestations, and prognosis. J Am Acad Dermatol. 78 (6): 1035-1044. https://doi.org/10.1016/j.jaad.2017.05.059; PMid:29754885
Krüger L, Schmitt E. (1995). Solitary involvement of the fourth thoracic vertebral body with eosinophilic granuloma and development of incomplete paraparesis. Eur Spine J. 4 (5): 313-316. https://doi.org/10.1007/BF00301042; PMid:8581534
Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR et al. (2020). Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 395: 1907-1918.
Lee LYW, Cazier J-B, Starkey T, Briggs SEW, Arnold R, Bisht V et al. (2020). COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 21: 1309-1316.
Leonidas JC, Guelfguat M, Valderrama E. (2003). Langerhans' cell histiocytosis. Lancet. 361: 1293-1295. https://doi.org/10.1016/S0140-6736(03)12990-X; PMid:12699969
Liu W, Wang L, Liu M, Li G. (2016). Pituitary Morphology and Function in 43 Children with Central Diabetes Insipidus. Int J Endocrinol. 2016: 6365830. Epub 2016 Mar 29. https://doi.org/10.1155/2016/6365830; PMid:27118970 PMCid:PMC4828552
Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA et al. (2021). COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 35: 2885-2894. https://doi.org/10.1038/s41375-021-01302-5; PMid:34079042 PMCid:PMC8171362
Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S et al. (2020). The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transpl. 55: 2071-2076. https://doi.org/10.1038/s41409-020-0919-0; PMid:32404975 PMCid:PMC7220575
Lü GH, Li J, Wang XB, Wang B, Phan K. (2014). Surgical treatment based on pedicle screw instrumentation for thoracic or lumbar spinal Langerhans cell histiocytosis complicated with neurologic deficit in children. Spine J. 14 (5): 768-776. https://doi.org/10.1016/j.spinee.2013.06.104; PMid:24035731
Lytvyn H, Basa N, Stasiv M, Troyanovska O, Dorosh O. (2020). Difficulties in diagnosing of measles inclusion body encephalitis in a child with acute lymphoblastic leukemia. IDCases 21: e00877. https://doi.org/10.1016/j.idcr.2020.e00877; PMid:32637321 PMCid:PMC7327900
McClain KL, Picarsic J, Chakraborty R, Zinn D, Lin H, Abhyankar H et al. (2018). CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 124 (12): 2607-2620. https://doi.org/10.1002/cncr.31348; PMid:29624648 PMCid:PMC6289302
McKenzie S, Vecerek N, Kang Y, Knowles B, Hogeling M. (2019). А neonatal pustule: Langerhans cell histiocytosis. Dermatol Online J. 25 (8): 13030/qt6hr0w31v. https://doi.org/10.5070/D3258045129; PMid:31553864
Minkov M, Pötschger U, Thacker N, Astigarraga I, Braier J, Donadieu J et al. (2021). Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis. J Pediatr. 237: 65-70.e3. https://doi.org/10.1016/j.jpeds.2021.06.016; PMid:34146548
Möhn N, Skripuletz T, Stangel M. (2018). Neurological complications of infections with (novel) enteroviruses. Nervenarzt. 89 (12): 1320-1331. https://doi.org/10.1007/s00115-018-0619-9; PMid:30259057
Morimoto A, Shioda Y, Sakamoto K, Imamura T, Imashuku S. (2022). Bone lesions of Langerhans cell histiocytosis triggered by trauma in children. Japan LCH Study Group. Pediatr Int. 64 (1): e15199. https://doi.org/10.1111/ped.15199; PMCid:PMC9541900
Munn S, Chu AC. (1998). Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am. 12: 269-286. https://doi.org/10.1016/S0889-8588(05)70510-4; PMid:9561900
Navaeian A, Mahmoudi S, Pourakbari B, Bakhtiari M, Khodabandeh M, Abdolsalehi MR, Sharari AS, Mamishi S. (2021). COVID-19 infection in children with underlying malignancies in Iran. J Basic Clin Physiol Pharmacol. 33 (1): 79-84. https://doi.org/10.1515/jbcpp-2021-0057; PMid:34192829
Nemet AY, Danks J, Grigg J. (2008). A 7th nerve palsy in a child with Langerhans histiocytosis. Orbit. 27 (2): 123-125. https://doi.org/10.1080/01676830701375785; PMid:18415873
Odoom JK, Obodai E, Boateng G, Diamenu S, Attiku K, Avevor P et al. (2021). Detection of vaccine-derived poliovirus circulation by environmental surveillance in the absence of clinical cases. Hum Vaccin Immunother. 17 (7): 2117-2124. https://doi.org/10.1080/21645515.2020.1852009; PMid:33517832 PMCid:PMC8189041
Padmanaban K, Kamalakaran A, Raghavan P, Palani T, Rajiah D. (2022). Langerhans Cell Histiocytosis of the Mandible. Cureus. 14 (8): e28222. https://doi.org/10.7759/cureus.28222; PMid:36158441 PMCid:PMC9486456
Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F et al. (2020). COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 288: 192-206. https://doi.org/10.1111/joim.13091; PMid:32348588 PMCid:PMC7267177
Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F et al. (2020). Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 7: e737-745. https://doi.org/10.1016/S2352-3026(20)30251-9; PMid:32798473
Peng XS, Pan T, Chen LY, Huang G, Wang J. (2009). Langerhans' cell histiocytosis of the spine in children with soft tissue extension and chemotherapy. Int Orthop. 33 (3): 731-736. https://doi.org/10.1007/s00264-008-0529-8; PMid:18338168 PMCid:PMC2903089
Puri I, Garg D, Srivastava AK, Singh L, Shukla G, Goyal V. (2019). Langerhans Cell Histiocytosis Presenting With Late-Onset Sporadic Ataxia. Mov Disord Clin Pract. 6 (8): 716-718. https://doi.org/10.1002/mdc3.12830; PMid:31745485 PMCid:PMC6856461
Ren FL, Skipper DC, Elbendary A, Tan Q, Elston DM. (2020). Cutaneous manifestations of Langerhans cell histiocytosis in children: a retrospective cohort study of 43 patients. J Eur Acad Dermatol Venereol. 34 (10): e640-e642. https://doi.org/10.1111/jdv.16509
Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S. (2019). Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: Results from the JLSG-96/02 studies. Japan LCH Study Group (JLSG). Pediatr Blood Cancer. 66 (1): e27454. https://doi.org/10.1002/pbc.27454; PMid:30207064
Simko SJ, Garmezy B, Abhyankar H, Lupo PJ, Chakraborty R, Lim KP et al. (2014). Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 165 (5): 990-996. https://doi.org/10.1016/j.jpeds.2014.07.063; PMid:25441388 PMCid:PMC4254414
Spicer J, Chamberlain C, Papa S. (2020). Provision of cancer care during the COVID-19 pandemic. Nat Rev Clin Oncol. 17: 329-331. https://doi.org/10.1038/s41571-020-0370-6; PMid:32296166 PMCid:PMC7156894
Styczynski J, Cesaro S, von Lilienfeld-Toal M, Marchesi F, Gil L, Mikulska M et al. (2022). Current attitude to deferral of cellular therapy or nontransplant chemotherapy due to SARS-CoV-2 asymptomatic infection: Survey of Infectious Diseases Working Party EBMT. Transpl Infect Dis. 24: e13773. https://doi.org/10.1111/tid.13773; PMid:34918856
Styczynski J, Czyzewski K, Wysocki M et al. (2016). Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. Clin Microbiol Infect. 22 (2): 179 e171-179 e110. https://doi.org/10.1016/j.cmi.2015.10.017; PMid:26493843
Titgemeyer C, Grois N, Minkov M, Flucher-Wolfram B, Gatterer-Menz I, Gadner H. (2001). Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 37: 108-114. https://doi.org/10.1002/mpo.1178; PMid:11496348
Troyanovska O, Dorosh O, Lytvyn H, Tsymbalyuk I, Vorobel O, Stepanyuk O et al. (2022). Characteristics of COVID-19 in pediatric patients with hematological malignancies. Acta Haematologica Polonica. 53 (4): 273-276. https://doi.org/10.5603/AHP.a2022.0035
Vaiani E, Felizzia G, Lubieniecki F, Braier J, Belgorosky A. (2021). Paediatric Langerhans Cell Histiocytosis Disease: Long-Term Sequelae in the Hypothalamic Endocrine System. Horm Res Paediatr. 94 (1-2): 9-17. https://doi.org/10.1159/000517040; PMid:34167121
Wang J-G, Zhong Z-J, Mo Y-F, Wang L-C, Chen R. (2021). Epidemiological features of coronavirus disease 2019 in children: a meta-analysis. Eur Rev Med Pharm Sci. 25: 1146-1157.
Węcławek-Tompol J, Zakrzewska Z, Gryniewicz-Kwiatkowska O, Pierlejewski F, Bień E, Zaucha-Prażmo A et al. (2021). COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study. J Hematol Oncol. 14(1): 163. https://doi.org/10.1186/s13045-021-01181-4; PMid:34635137 PMCid:PMC8503711
WHO. (2022). WHO announces COVID-19 outbreak a pandemic. URL: https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic.
Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH et al. (2020). Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 4: 5966-5975. https://doi.org/10.1182/bloodadvances.2020003170; PMid:33278301 PMCid:PMC7724912
Wu C, Li K, Hei Y, Lan P, Mu X. (2019). MR imaging features of orbital Langerhans cell Histiocytosis. BMC Ophthalmol. 19 (1): 263. https://doi.org/10.1186/s12886-019-1269-9; PMid:31856763 PMCid:PMC6923963
Zhang AW, Morjaria S, Kaltsas A, Hohl TM, Parameswaran R, Patel D et al. (2022). The effect of neutropenia and filgrastim (G-CSF) in cancer patients with COVID-19 infection. Clin Infect Dis. 74: 567-574. https://doi.org/10.1093/cid/ciab534; PMid:34111237 PMCid:PMC8406899
Zhang XH, Zhang J, Chen ZH, Sai K, Chen YS, Wang J, Ke C, Guo CC, Chen ZP, Mou YG. (2017). Langerhans cell histiocytosis of skull: a retrospective study of 18 cases. Ann Palliat Med. 6 (2): 159-164. https://doi.org/10.21037/apm.2016.11.04; PMid:28061539
Zhou W, Rao J, Li C. (2019). Isolated Langerhans cell histiocytosis in the hypothalamic-pituitary region: a case report. BMC Endocr Disord. 19 (1): 143. https://doi.org/10.1186/s12902-019-0474-0; PMid:31856773 PMCid:PMC6924050
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Modern pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
